Epizyme, Inc.
(NASDAQ : EPZM)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
1.01%296.831.4%$601.48m
AMGNAmgen, Inc.
0.32%236.741.3%$495.31m
GILDGilead Sciences, Inc.
-2.75%65.771.0%$370.34m
REGNRegeneron Pharmaceuticals, Inc.
1.15%376.422.6%$305.23m
VRTXVertex Pharmaceuticals, Inc.
-0.71%218.981.9%$275.99m
ILMNIllumina, Inc.
0.85%324.723.5%$241.12m
CLVSClovis Oncology, Inc.
-4.24%12.8614.7%$219.13m
SRPTSarepta Therapeutics, Inc.
31.43%132.0514.6%$207.70m
ALXNAlexion Pharmaceuticals, Inc.
-1.82%110.422.0%$199.61m
ARWRArrowhead Pharmaceuticals, Inc.
-1.28%66.4611.4%$199.52m
AAgilent Technologies, Inc.
-1.30%83.711.6%$164.84m
EXASEXACT Sciences Corp.
2.08%87.2024.0%$164.17m
BLUEbluebird bio, Inc.
6.78%89.7514.2%$152.73m
GBTGlobal Blood Therapeutics, Inc.
-0.01%76.886.0%$140.08m
BOLDAudentes Therapeutics, Inc.
0.05%59.401.4%$136.27m

Company Profile

Epizyme, Inc. is a clinical-stage biopharmaceutical company, which engage in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. It also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.